STOCK TITAN

MAIA Biotechnology Inc - MAIA STOCK NEWS

Welcome to our dedicated news page for MAIA Biotechnology (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MAIA Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MAIA Biotechnology's position in the market.

Rhea-AI Summary
MAIA Biotechnology, Inc. completes enrollment in Phase 2 THIO-101 trial for advanced non-small cell lung cancer, showing promising results and potential as a new standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
clinical trial
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications. The research demonstrates the immune-enhancing, metastasis-reducing effects of MAIA’s telomere-targeting agent THIO in several well-characterized in vitro and in vivo models of SCLC. The findings highlight a unique dual mechanism of action for THIO as a first-in-clinic telomere-targeted anticancer agent for potential treatment of SCLC. THIO has been awarded orphan drug designation (ODD) by the FDA for SCLC treatment, and the company has entered the Phase 2 planning stage for a clinical trial of THIO in SCLC along with two other cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology, Inc. has announced the publication of a global Patent Cooperation Treaty (PCT) application for their telomere-targeting platform, extending potential cancer therapies using dinucleotide compounds. The new patent would provide coverage through 2043 and expand the value of their innovative cancer treatment platform globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
none
Rhea-AI Summary
MAIA Biotechnology, Inc. announces positive interim data for THIO-101 Phase 2 trial in non-small cell lung cancer, with sustained disease control rates. The company also outlines key clinical milestones for 2024, maintaining a robust clinical pipeline in hard-to-treat cancer indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.33%
Tags
clinical trial
-
Rhea-AI Summary
MAIA Biotechnology, Inc. (MAIA) announced its participation in the Biotech Showcase™ 2024 investor conference in San Francisco. Chairman and CEO Vlad Vitoc, MD, MBA, will present an update on the Company’s lead program, THIO, a potential first-in-class telomere targeting agent for non-small cell lung cancer (NSCLC). Preliminary data from the ongoing THIO-101 Phase 2 trial includes an unprecedented disease control rate (DCR) of 100% in second-line NSCLC treatment. Dr. Vitoc will discuss multiple value-driving Company milestones expected in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.89%
Tags
conferences
-
Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced the selection of a dose for THIO-101, a Phase 2 clinical trial evaluating its lead asset, THIO, in combination with Regeneron’s anti-PD-1 cemiplimab in patients with advanced non-small cell lung cancer (NSCLC). The selected dose of 180mg/cycle showed better safety profile and outperformed other doses in efficacy measures, exceeding disease control rate thresholds and showing promising preliminary response rates. MAIA plans to pursue accelerated approval for THIO in the U.S. for the treatment of advanced NSCLC patients, believing in its potential to define the standard of care for this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
clinical trial
Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced the closing of a registered direct offering for 2,424,243 shares of common stock at $1.65 per share, alongside a private placement of unregistered warrants for the same number of shares. H.C. Wainwright & Co. acted as the exclusive placement agent, resulting in gross proceeds of approximately $4 million for MAIA. The net proceeds will be used for working capital, general corporate purposes, and research and development activities. The offering was made under a 'shelf' registration statement on Form S-3, declared effective by the SEC. Unregistered warrants issued in the private placement may not be reoffered or resold in the United States without registration or an applicable exemption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.57%
Tags
offering
-
Rhea-AI Summary
MAIA Biotechnology Inc. (NYSE:MAIA) has received orphan drug designation from the U.S. FDA for its cancer telomere-targeting agent, THIO, for the treatment of glioblastoma, a rare and aggressive form of brain cancer. The designation highlights the FDA's recognition of THIO's potential to treat multiple types of cancers, including rare ones like glioblastoma. With limited treatment options available for glioblastoma patients, MAIA's lead program, THIO, has the potential to improve outcomes for these patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.57%
Tags
clinical trial
-
Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) Announces Registered Direct Offering and Private Placement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.73%
Tags
offering
Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced that the U.S. FDA has granted orphan drug designation to its lead asset THIO for the treatment of glioblastoma. This is the third ODD granted to THIO, highlighting its potential in treating multiple cancer indications. Expected market growth from $2.2 billion to $3.2 billion globally in the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
clinical trial
MAIA Biotechnology Inc

NYSE:MAIA

MAIA Rankings

MAIA Stock Data

44.01M
14.55M
22.05%
4.02%
2.61%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Chicago

About MAIA

maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia’s business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru